Clinical Trials in Tennessee

Showing 15141-15160 of 20,239 trials

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

NCT01462318

The primary objective of the study is to assess the immunogenicity of Daclizumab High Yield Process (DAC HYP) 150 mg administered every 4 weeks by subcutaneous (SC) injection using the pre-filled syringe (PFS) in participants with relapsing-remitting multiple sclerosis (RRMS). The secondary objectives of this study are to characterize the pharmacokinetics (PK) of DAC HYP following single and multiple doses of DAC HYP administered by the PFS in a subset of participants with RRMS and to evaluate the effect of DAC HYP on the PK of probe drugs for cytochrome P450 (CYP) isoenzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A).

Relapsing-Remitting Multiple Sclerosis

Biogen133 participantsStarted Nov 2011

Centennial, Colorado, United States • Washington D.C., District of Columbia, United States • Lake Barrington, Illinois, United States +16 more locations

COMPLETED29 miles

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

NCT00899769

RATIONALE: Studying samples of blood, tissue, and saliva in the laboratory from patients with cancer and from healthy volunteers may help doctors identify and learn more about biomarkers related to cancer. PURPOSE: This laboratory study is looking at biomarkers in patients with head and neck cancer and in healthy volunteers.

Head and Neck Cancer

Vanderbilt University Medical Center100 participantsStarted Apr 2005

Nashville, Tennessee, United States • Nashville, Tennessee, United States • Nashville, Tennessee, United States

An Open-Label Immunogenicity and Pharmacokinetics Study of Daclizumab High Yield Process Prefilled Syringe in Relapsing Remitting Multiple Sclerosis

Biomarkers in Patients With Head and Neck Cancer and in Healthy Volunteers

Find Trials by Condition in Tennessee

SinuSurf vs. Saline Solution in Normal Subjects

16 Week Efficacy and 2 Year Long Term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Micro-Layer Ablation of Barrett's Metaplasia- A Two-Phase, Multi-Center Trial - Extension of Follow-up to 5 Years

Vitamin D/Calcium Polyp Prevention Study

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

Pyridoxine and Topical Urea/Lactic Acid-Based Cream in Preventing Hand-Foot Syndrome in Patients Receiving Capecitabine for Breast Cancer or Other Cancer

Asthma Phenotypes in the Inner City

A Multicenter Study of NAP (AL-108) in Schizophrenia

PRO 140 for Human Immunodeficiency Virus Infection

Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Efficacy of Web-based Pain Self-management for Adolescents With Juvenile Idiopathic Arthritis

Stepped Enhancement of PTSD Services Using Primary Care (STEPS UP): A Randomized Effectiveness Trial

Pazopanib in Treating Patients With Recurrent Glioblastoma

Is Endothelial Function a Predictor of Successful Ablation Therapy Provided to Patients With Atrial Fibrillation?

Phase I Study of CBP501 and Cisplatin in Patients With Advanced Refractory Solid Tumors